Magnesium (Mg) and Neurodegeneration: A Comprehensive Overview of Studies on Mg Levels in Biological Specimens in Humans Affected Some Neurodegenerative Disorders with an Update on Therapy and Clinical Trials Supplemented with Selected Animal Studies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Dec 17

PMID 39684308

Authors

Agnieszka Scibior

Juan Llopis

Pawel P Dobrakowski

Tomasz Mecik-Kronenberg

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative diseases, characterized by neuron loss, are a group of neurological disorders that adversely affect the lives of millions of people worldwide. Although several medicines have been approved for managing neurodegenerative diseases, new therapies allowing for a significant slowdown in the progression of neurodegenerative syndromes are constantly being sought. Magnesium (Mg), a crucial mineral necessary for the functioning of organisms, is important to normal central nervous system (CNS) activity. Although the effects of this bioelement on the CNS are relatively well recognized, its role in the pathophysiology of neurological disorders in humans is not yet well characterized. Therefore, the main goal of this review is to collect data about a possible association between Mg and neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's Disease (PD), and Amyotrophic lateral sclerosis (ALS) in humans. Hence, the levels of Mg in blood, cerebrospinal fluid (CSF), urine, and hair from subjects with AD, PD, and ALS are compiled to detect possible variations in the levels of this mineral in the biological specimens of people with neurodegenerative illnesses. Additionally, the findings from an animal model are summarized to offer the reader a deeper insight into studies on Mg in the context of neuroprotection and neurodegeneration. Data provided in the present review indicate that Mg, due to its neuroprotective, antioxidant, anti-inflammatory, and mitochondrial-supportive properties, could be a potential therapeutic agent for AD, PD, and ALS. However, more epidemiological studies with standardized methods of dietary assessment and Mg measurement are necessary to recognize its exact role in neurodegenerative disorders. Moreover, extensive well-designed clinical trials are also needed to establish definitive therapeutic protocols and optimal dosages, and to ensure long-term safety of this mineral supplementation in AD, PD, and ALS patients.

References

Scholefield M, Church S, Xu J, Patassini S, Roncaroli F, Hooper N . Widespread Decreases in Cerebral Copper Are Common to Parkinson's Disease Dementia and Alzheimer's Disease Dementia. Front Aging Neurosci. 2021; 13:641222. PMC: 7966713. DOI: 10.3389/fnagi.2021.641222. View

Hoane M, Irish S, Marks B, Barth T . Preoperative regimens of magnesium facilitate recovery of function and prevent subcortical atrophy following lesions of the rat sensorimotor cortex. Brain Res Bull. 1998; 45(1):45-51. DOI: 10.1016/s0361-9230(97)00288-8. View

Alimonti A, Ristori G, Giubilei F, Stazi M, Pino A, Visconti A . Serum chemical elements and oxidative status in Alzheimer's disease, Parkinson disease and multiple sclerosis. Neurotoxicology. 2007; 28(3):450-6. DOI: 10.1016/j.neuro.2006.12.001. View

Slutsky I, Abumaria N, Wu L, Huang C, Zhang L, Li B . Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010; 65(2):165-77. DOI: 10.1016/j.neuron.2009.12.026. View

van de Mortel L, Thomas R, van Wingen G . Grey Matter Loss at Different Stages of Cognitive Decline: A Role for the Thalamus in Developing Alzheimer's Disease. J Alzheimers Dis. 2021; 83(2):705-720. PMC: 8543264. DOI: 10.3233/JAD-210173. View

Bird C, Burgess N . The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci. 2008; 9(3):182-94. DOI: 10.1038/nrn2335. View

Yoshida S, Kihira T, Yase Y . [Etiology of Kii ALS/PDC, featuring a mineral hypothesis]. Rinsho Shinkeigaku. 2008; 47(11):970-3. View

Yamanaka R, Shindo Y, Hotta K, Suzuki K, Oka K . GABA-Induced Intracellular Mg Mobilization Integrates and Coordinates Cellular Information Processing for the Maturation of Neural Networks. Curr Biol. 2018; 28(24):3984-3991.e5. DOI: 10.1016/j.cub.2018.10.044. View

Barbour R, Gebrewold A, Altura B, Altura B . Optical spectroscopy and prevention of deleterious cerebral vascular effects of ethanol by magnesium ions. Eur J Pharmacol. 2002; 447(1):79-86. DOI: 10.1016/s0014-2999(02)01831-9. View

10.

Vink R . Magnesium in the CNS: recent advances and developments. Magnes Res. 2016; 29(3):95-101. DOI: 10.1684/mrh.2016.0408. View

11.

Jin X, Liu M, Zhang D, Gao H, Wei M . Elevated circulating magnesium levels in patients with Parkinson's disease: a meta-analysis. Neuropsychiatr Dis Treat. 2018; 14:3159-3168. PMC: 6250112. DOI: 10.2147/NDT.S186209. View

12.

Barbagallo M, Belvedere M, Di Bella G, Dominguez L . Altered ionized magnesium levels in mild-to-moderate Alzheimer's disease. Magnes Res. 2011; 24(3):S115-21. DOI: 10.1684/mrh.2011.0287. View

13.

Bostrom F, Hansson O, Blennow K, Gerhardsson L, Lundh T, Minthon L . Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2009; 28(4):314-9. DOI: 10.1159/000249145. View

14.

Bocca B, Alimonti A, Senofonte O, Pino A, Violante N, Petrucci F . Metal changes in CSF and peripheral compartments of parkinsonian patients. J Neurol Sci. 2006; 248(1-2):23-30. DOI: 10.1016/j.jns.2006.05.007. View

15.

Yasui M, Ota K . Aluminum decreases the magnesium concentration of spinal cord and trabecular bone in rats fed a low calcium, high aluminum diet. J Neurol Sci. 1998; 157(1):37-41. DOI: 10.1016/s0022-510x(98)00075-6. View

16.

Bhatia S, Rawal R, Sharma P, Singh T, Singh M, Singh V . Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development. Curr Neuropharmacol. 2021; 20(4):675-692. PMC: 9878959. DOI: 10.2174/1570159X19666210517114016. View

17.

Moon H, Paek S . Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol. 2015; 24(2):103-16. PMC: 4479806. DOI: 10.5607/en.2015.24.2.103. View

18.

Anirudhan A, Angulo-Bejarano P, Paramasivam P, Manokaran K, Manjunath Kamath S, Murugesan R . RPL6: A Key Molecule Regulating Zinc- and Magnesium-Bound Metalloproteins of Parkinson's Disease. Front Neurosci. 2021; 15:631892. PMC: 8006920. DOI: 10.3389/fnins.2021.631892. View

19.

Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P . Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023; 8(1):73. PMC: 9944326. DOI: 10.1038/s41392-023-01353-3. View

20.

Ozawa M, Ninomiya T, Ohara T, Hirakawa Y, Doi Y, Hata J . Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. J Am Geriatr Soc. 2012; 60(8):1515-20. DOI: 10.1111/j.1532-5415.2012.04061.x. View